1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
• 化学式: C₁₀H₁₁F₃N₂O₅
• 分子量: 296.2
• InChiKey: VSQQQLOSPVPRAZ-JXBXZBNISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• [EN] CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT<br/>[FR] TRIFLUOROMÉTHYLATION INNÉE EXEMPTE DE CATALYSEUR ET NEUTRE À L'OXYDORÉDUCTION, ET ALKYLATION DE COMPOSÉS (HÉTÉRO)AROMATIQUES ACTIVÉS PAR LA LUMIÈRE
  申请人：THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV

  公开号：WO2019060998A1

  公开（公告）日：2019-04-04

  The present disclosure relates to reagents and method for performing trifluoromethylation, difluoromethylation or alkylation of aromatic or heteroaromatic rings in a redox-neutral manner without any catalyst which are enabled by light. In addition, there are methods for synthesizing the starting reagents used in the trifluoromethylation, difluoromethylation or alkylation reactions.

  本公开涉及一种在无需任何催化剂的情况下通过光启动对芳香或杂环芳香环进行三氟甲基化、二氟甲基化或烷基化的试剂和方法。此外，还有用于合成进行三氟甲基化、二氟甲基化或烷基化反应中所使用的起始试剂的方法。
• METHOD FOR PREPARING TRIFLURIDINE
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US20210292356A1

  公开（公告）日：2021-09-23

  The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and performing further reaction to obtain trifluridine.

  本申请涉及一种制备三氟胸苷的方法，包括在第一溶剂中，在酸的存在下，将式III化合物与式IV化合物反应，以获得式II化合物，并进行进一步的反应以获得三氟胸苷。
• 5'-POSITION DIBENZYL MONOPHOSPHATE DERIVATIVE OF NUCLEOSIDE-BASED ANTICANCER AGENT OR ANTIVIRUS AGENT
  申请人：Ohara Pharmaceutical Co., Ltd.

  公开号：US20200123190A1

  公开（公告）日：2020-04-23

  To provide, in place of injected agents (nucleoside-based anticancer agents or antivirus agents) clinically used as therapeutic drugs for cancer or virus infections, a medicine that has high stability with respect to various hydrolytic metabolic enzymes, is absorbed into the body even by oral administration, and exhibits a cytocidal effect by being incorporated into a DNA and RNA biosynthetic route and inhibiting the modification and extension of DNA and RNA or inhibiting reverse transcriptases or inhibiting protein synthesis. The aforementioned problem is solved by a novel compound represented by formula (I). (In the formula, D is the 5′-position moiety of a nucleoside-based anticancer agent or an antivirus agent, and R 1 and R 2 are each a benzyl group that may have the same substituent or different substituents.)

  提供一种替代核苷酸类抗癌药物或抗病毒药物注射剂的药物，该药物具有对各种水解代谢酶高稳定性，即使口服也能被身体吸收，并通过被纳入到DNA和RNA生物合成途径中并抑制DNA和RNA的修饰和延伸或抑制逆转录酶或抑制蛋白质合成而表现出细胞毒性的特点。上述问题通过一种新化合物（I）来解决。（在公式中，D是核苷酸类抗癌药物或抗病毒药物的5'-位置基团，R1和R2分别是苯甲基，可以具有相同的取代基或不同的取代基。）
• [EN] METHOD FOR PREPARING TRIFLURIDINE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE TRIFLURIDINE<br/>[ZH] 一种曲氟尿苷的制备方法
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

  公开号：WO2020020208A1

  公开（公告）日：2020-01-30

  本申请涉及曲氟尿苷的制备方法，包括式III化合物和式IV化合物在酸存在下，在第一溶剂中反应得到式II化合物，并进一步反应得到曲氟尿苷。
• NUCLEIC ACID BASE HAVING PERFLUOROALKYL GROUP AND METHOD FOR PRODUCING THE SAME
  申请人：Tosoh Corporation

  公开号：EP1947092A1

  公开（公告）日：2008-07-23

  Provided is a simple and efficient production process of a nucleobase having a perfluoroalkyl group. A nucleobase (for example, uracils, cytosines, adenines, guanines, hypoxanthines, xanthines, or the like) is reacted with a perfluoroalkyl halide in the presence of a sulfoxide, a peroxide and an iron compound to produce a perfluoroalkyl-substituted nucleobase, which is useful as an intermediate for medical drugs, economically.

  本发明提供了一种具有全氟烷基的核碱基的简单而高效的生产工艺。 核碱基（例如尿嘧啶、胞嘧啶、腺嘌呤、鸟嘌呤、次黄嘌呤、黄嘌呤或类似物）在亚砜、过氧化物和铁化合物的存在下与全氟烷基卤化物反应，生成全氟烷基取代的核碱基，该核碱基可经济地用作医疗药物的中间体。